118 related articles for article (PubMed ID: 7721628)
1. A question-filled future for dose escalation in prostate cancer.
Hanks GE
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):267-9. PubMed ID: 7721628
[No Abstract] [Full Text] [Related]
2. Dose escalation by proton irradiation for adenocarcinoma of the prostate.
Cox JD
Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):265-6. PubMed ID: 7721627
[No Abstract] [Full Text] [Related]
3. A question-filled future for dose-escalation in prostate cancer--regarding Shipley et al., IJROBP 32:3-12; 1995.
Hanks GE
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):891-3. PubMed ID: 7646684
[No Abstract] [Full Text] [Related]
4. Improved quality of life following radical radiation therapy for early stage carcinoma of the prostate.
Leibel SA; Pino y Torres JL; Order SE
Urol Clin North Am; 1980 Oct; 7(3):593-604. PubMed ID: 7456172
[No Abstract] [Full Text] [Related]
5. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
[TBL] [Abstract][Full Text] [Related]
6. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer.
Pinkawa M; Piroth MD; Holy R; Fischedick K; Schaar S; Borchers H; Heidenreich A; Eble MJ
Radiother Oncol; 2010 Jul; 96(1):25-9. PubMed ID: 20231039
[TBL] [Abstract][Full Text] [Related]
8. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.
Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of radiotherapy for prostate cancer.
Pisansky TM
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1663-4; author repply 1664. PubMed ID: 15590203
[No Abstract] [Full Text] [Related]
11. Tumor response and treatment complications in radiotherapy of localized prostate cancer.
Strnad V; Tacev T; Prokes B; Ott O; Krystof V; Svobodova M; Rasovska O; Konecny M
Strahlenther Onkol; 1990 Nov; 166(11):728-32. PubMed ID: 2124375
[TBL] [Abstract][Full Text] [Related]
12. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy of T1c prostate cancer.
Ben-Josef E; Porter AT
Semin Urol Oncol; 1995 Aug; 13(3):191-6. PubMed ID: 8521132
[TBL] [Abstract][Full Text] [Related]
14. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995.
Thames HD; Kuban D; Levy LB; Horwitz EM; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Radiother Oncol; 2010 Jul; 96(1):6-12. PubMed ID: 20400191
[TBL] [Abstract][Full Text] [Related]
15. Brachytherapy for clinically localized prostate cancer: optimal patient selection.
Kollmeier MA; Zelefsky MJ
Arch Esp Urol; 2011 Oct; 64(8):847-57. PubMed ID: 22052766
[TBL] [Abstract][Full Text] [Related]
16. [Curative radiotherapy in stage C prostatic carcinoma. Experiences with radiotherapy-endocrine treatment].
Klosterhalfen H; Becker H; Köllermann MW; Altenähr E
Urologe A; 1983 Sep; 22 Suppl():360-6. PubMed ID: 6314624
[TBL] [Abstract][Full Text] [Related]
17. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
18. Radical external beam radiation therapy for prostate carcinoma.
Garrett PG; Herman JG; Rawlings GA; Hawkins NV; Gospodarowicz MK; Keen CW; Rider WD
J Can Assoc Radiol; 1984 Jun; 35(2):139-43. PubMed ID: 6480665
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate.
Myers MA; Hagan MP; Todor D; Gilbert L; Mukhopadhyay N; Randolf J; Heimiller J; Anscher MS
Brachytherapy; 2012; 11(4):292-8. PubMed ID: 22464911
[TBL] [Abstract][Full Text] [Related]
20. Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome.
Hinnen KA; Moerland MA; Battermann JJ; van Roermund JG; Monninkhof EM; Jürgenliemk-Schulz IM; van Vulpen M
Radiother Oncol; 2010 Jul; 96(1):30-3. PubMed ID: 20215039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
